Skip to main content

REVIEW article

Front. Nephrol.
Sec. Clinical Research in Nephrology
Volume 4 - 2024 | doi: 10.3389/fneph.2024.1511596

HIF-PHI Daprodustat role and clinical implication in dialysis-dependent and non-dialysis-dependent chronic kidney disease anemic patients: A general review

Provisionally accepted
Yousuf Abdulkarim Waheed Yousuf Abdulkarim Waheed 1,2Liu Jie Liu Jie 3Shifaa Almayahe Shifaa Almayahe 4Dong Sun Dong Sun 1,2,5*
  • 1 The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
  • 2 Clinical Research Center For Kidney Disease Xuzhou Medical University, Xuzhou, Jiangsu Province, China
  • 3 Department of Radiation, Second Affiliated Hospital, Xuzhou Medical University, Xuzhou, Jiangsu Province, China
  • 4 Medical college, University of Fallujah, Al Anbar Iraq, Al Anbar, Iraq
  • 5 Department of Internal Medicine and Diagnostics, Xuzhou Medical University, Xuzhou, Xuzhou, China

The final, formatted version of the article will be published soon.

    Chronic kidney disease (CKD) patients often suffer from complications such as anemia as the kidney function declines. More than 25% of CKD hemodialysis patients in China are complicated with renal anemia due to renal and hepatic impairment production of erythropoietin (EPO). In recent years, prolyl hydroxylase domain (PHD) inhibitors have been approved in China and Japan for the treatment of CKD patients complicated with anemia. Daprodustat is a novel orally administrated active hypoxiainduced factor-prolyl hydroxylase inhibitor (HIF-PHI) that may improve the quality of life, and ischemic conditions such as peripheral arterial disease (PAD), stimulate the synthesis of endogenous EPO and can effectively induce the red blood cells production. It has been shown to increase EPO levels which can lead to an increase in hemoglobin (Hgb), hematocrit, and red blood cell counts. Clinical studies have shown its effectiveness in dialysis and non-dialysis CKD anemic patients. In this literature review, we will focus on the mechanism and metabolism of the drug, the clinical applications in dialysis and non-dialysis CKD patients, and we will summarize the adverse reactions.

    Keywords: Daprodustat, Anemia, Chronic Kidney Disease, Erythropoietin, Dialysis

    Received: 15 Oct 2024; Accepted: 02 Dec 2024.

    Copyright: © 2024 Waheed, Jie, Almayahe and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Dong Sun, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.